valeryl-guanidine | 55034-34-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: valeryl-guanidine
• 英文别名: Valeryl-guanidin；N-(diaminomethylidene)pentanamide
• CAS: 55034-34-9
• 化学式: C₆H₁₃N₃O
• mdl: MFCD19209157
• 分子量: 143.189
• InChiKey: RVGWCKGDBVOPPW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  81.5
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  valeryl-guanidine 生成 6-(1-butyl)-2,4-diamino-1,3,5-triazine
  参考文献：
  名称：

  US2408694

  摘要：

  公开号：

文献信息

• Substituted azetidinones
  申请人：Bannister Thomas

  公开号：US20070105832A1

  公开（公告）日：2007-05-10

  Compounds are provided which have the structure Wherein A, B, C, D, m, Y, Ra, Rc, Rd, and Rd′ are as described herein, and which are useful as inhibitors of tryptase, thrombin, trypsin, Factor Xa, Factor VIIa, Factor XIa, and urokinase-type plasminogen activator and may be employed in preventing and/or treating asthma, chronic asthma, allergic rhinitis, and thrombotic disorders.

  提供了化合物，其结构如下：其中A、B、C、D、m、Y、Ra、Rc、Rd和Rd'如本文所述，并且这些化合物可作为抑制剂用于抑制组胺酶、凝血酶、胰蛋白酶、Xa因子、VIIa因子、XIa因子和尿激酶型纤溶酶原激活剂，并可用于预防和/或治疗哮喘、慢性哮喘、过敏性鼻炎和血栓性疾病。
• SUBSTITUTED AZETIDINONES
  申请人：Bannister Thomas

  公开号：US20090143351A1

  公开（公告）日：2009-06-04

  Compounds are provided which have the structure Wherein A, B, C, D, m, Y, Ra, Rc, Rd, and Rd′ are as described herein, and which are useful as inhibitors of tryptase, thrombin, trypsin, Factor Xa, Factor VIIa, Factor XIa, and urokinase-type plasminogen activator and may be employed in preventing and/or treating asthma, chronic asthma, allergic rhinitis, and thrombotic disorders.

  提供了具有以下结构的化合物： 其中A、B、C、D、m、Y、Ra、Rc、Rd和Rd′如本文所述，可用作抑制剂，包括酪氨酸酶、凝血酶、胰蛋白酶、因子Xa、因子VIIa、因子XIa和尿激酶型纤溶酶原激活剂，并可用于预防和/或治疗哮喘、慢性哮喘、过敏性鼻炎和血栓性疾病。
• Human adam-10 inhibitors
  申请人：Brown S. David

  公开号：US20090143386A1

  公开（公告）日：2009-06-04

  The present invention provides compounds useful for inhibiting the ADAM-10 protein. Such compounds are useful in the in vitro study of the role of ADAM-10 (and its inhibition) in biological processes. The present invention also comprises pharmaceutical compositions comprising one or more ADAM-10 inhibitors according to the invention in combination with a pharmaceutically acceptable carrier. Such compositions are useful for the treatment of cancer, arthritis, and diseases related to angiogenesis. Correspondingly, the invention also comprises methods of treating forms of cancer, arthritis, and diseases related to angiogenesis in which ADAM-10 plays a critical role. The invention also provides methods for making bis-aryl ether sulfonyl chlorides and ADAM-10 modulators therefrom.

  本发明提供了用于抑制ADAM-10蛋白的化合物。这些化合物在体外研究ADAM-10（及其抑制）在生物过程中的作用方面非常有用。本发明还包括与一种或多种本发明的ADAM-10抑制剂结合的药学上可接受的载体组成的制药组合物。这样的组合物在治疗癌症、关节炎和与血管生成相关的疾病方面非常有用。相应地，本发明还包括治疗癌症、关节炎和与血管生成相关的疾病的方法，其中ADAM-10发挥关键作用。本发明还提供制备双芳基醚磺酰氯和ADAM-10调节剂的方法。
• Method for treatment of inflammatory skin disorders with inhibitors of IL-36 proteolytic processing
  申请人：THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY

  公开号：US10744179B2

  公开（公告）日：2020-08-18

  This invention relates to the use of an agent capable of inhibiting IL-36 proteolytic processing for the treatment and/or reduction of inflammation in a subject. Advantageously, the agent prevents the production of a biologically active IL-36 to prevent and/or reduce the pro-inflammatory effects of IL-36. The invention also relates to a method for treatment and/or reduction of inflammation and compositions for treating and/or reducing inflammation.

  本发明涉及一种能够抑制 IL-36 蛋白水解加工的制剂在治疗和/或减轻受试者炎症方面的用途。有利的是，该制剂能阻止生物活性 IL-36 的产生，从而防止和/或减少 IL-36 的促炎作用。本发明还涉及一种治疗和/或减轻炎症的方法以及治疗和/或减轻炎症的组合物。
• USE OF INHIBITORS OF IL-36 PROTEOLYTIC PROCESSING FOR THE TREATMENT AND/OR REDUCTION OF INFLAMMATION
  申请人：THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY

  公开号：US20170281716A1

  公开（公告）日：2017-10-05

  This invention relates to the use of an agent capable of inhibiting IL-36 proteolytic processing for the treatment and/or reduction of inflammation in a subject. Advantageously, the agent prevents the production of a biologically active IL-36 to prevent and/or reduce the pro-inflammatory effects of IL-36. The invention also relates to a method for treatment and/or reduction of inflammation and compositions for treating and/or reducing inflammation.